Dr. Reddy’s, American Remedies merger through - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dr. Reddy’s, American Remedies merger through

Mar 7, 2000

The legal merger between Dr Reddy’s Laboratories (DRL) and American Remedies (ARL) is through. The merger ratio has been fixed at 1:12 i.e. 1 share of DRL for every 12 shares of ARL. DRL is one of the fastest growing companies in the pharmaceutical sector having a 1.4% market share in domestic formulations. The company has grown from being a bulk drug company to a respected formulation based company. It has products such as omeprazole (gastro–intestinal), ciprolet (anti–infective) Nise (pain and fever), Enam (cardiovascular) etc.

ARL’s product range includes Mucolite, Becozinc, Antoxid, GLA, BioE, which account for 60% of the company’s estimated Rs 1 bn sales (FY 2000 estimates). More importantly, ARL has a prescription base of around one lakh doctors which provides DRL with another channel to sell its own products in the domestic market.

DRL acquired a 45% stake in ARL a few months back and has already acquired a further 15–20% stake from the associates of ARL’s promoters. An open offer for to acquire another 20% from the company’s shareholders enabled DRL to take its holding to 84% of the equity of ARL. In a way the legal merger is a formality for DRL since the company has already integrated the manufacturing as well as the marketing network of ARL into its operations.

Market View:
Analysts are convinced of the seriousness of the R & D efforts of the company and have rated the stock as a buy. The company has three new original molecules in its research pipeline. One is an anti–cancer compound, another is a Cox II inhibitor (anti–pain) and third was a compound indicated for metabolic disorders. The company foresees licensing out two of these to MNCs for clinical trials in the near future. Perhaps the only dampener could be the fact that 20% of its earnings from its exports to Russia would come under the tax net.


Equitymaster requests your view! Post a comment on "Dr. Reddy’s, American Remedies merger through". Click here!

  

More Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation (Fast Profits Daily)

Oct 9, 2020

How I picked an exciting stock using trends from both the commodity and equity markets.

The 'Seedhi Baat, No Bakwaas' View on ITC (Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now (Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

The Inflection Point for Defence Stocks is Getting Closer (Profit Hunter)

Oct 9, 2020

Few Indian defence companies could use their engineering capabilities to eventually become global leaders.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Oct 21, 2020 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - STRIDES PHARMA SCIENCE COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS